iBio Inc. (IBIO)
Symbol Info
Listed Symbol IBIO
Name iBio Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2019-06-30
Latest Fiscal Revenue $2,018,000
Latest Fiscal EPS $-0.94
Price Info
21 Day Moving Average $0.5093
21 Day EMA $0.509400
50 Day Moving Average $0.6051
50 Day EMA $0.578890
200 Day EMA $0.758220
200 Day Moving Average 0.761010
52 Week High $1.40
52 Week Low $0.37
52 Week Change $-36.532100
Alpha -0.037093
Beta 0.6650
Standard Deviation 0.198193
R2 0.013279
Periods 60
Share Information
10 Day Average Volume 322,302
20 Day Average Volume 249,342
30 Day Average Volume 287,512
50 Day Average Volume 1,277,234
Outstanding Shares 24,152,455
Float Shares 18,063,075
Percent Float 74.79%
Short Interest 1,010,389
Short Percent Float 4.20%
Short Interest Ratio 2.94
Short Date 2019-09-30
Holders
Institutions 26
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 14,074
Institute Holdings Percent 2.100000
Institute Sold Previous 3 Months 40,665
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 2
Insider Holdings Percent 30.90%
Insider Sold Previous 3 Months -
Insiders Shares Owned 6,089,380
Price Change
7 Day Price Change $0.0705000
7 Day Percent Change 15.67%
21 Day Price Change $-0.02
21 Day Percent Change -3.70%
30 Day Price Change $-0.0841
30 Day Percent Change -13.91%
Month To Date Price Change $-0.0195
Month To Date Percent -3.61%
90 Day Price Change $-0.1942
90 Day Percent Change -27.17%
Quarter To Date $-0.0195
Quarter To Date Percent -3.61%
180 Day Price Change $-0.3095
180 Day Percent Change -37.29%
200 Day Price Change $-0.329275
200 Day Percent Change -38.75%
Year To Date $-0.2329
Year To Date Percent -30.91%
Profile
Description iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products.
Details
Issue Type CS
Market Cap $12,571,353
Sec Type EQS
Auditor CohnReznick LLP
Total Shares Outstanding 24,152,455
CEO Robert B. Kay
Employees 55
Last Audit UE
Classification
CIK 0001420720
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 600 Madison Avenue
Suite 1601
New York, NY 10022-1737
Website https://www.biospace.com
Facisimile +1 302 356-1173
Telephone +1 302 355-0650
Email ir@ibioinc.com
Key Ratios
Profitability
EBIT Margin -777.8
EBITDA Margin -691.2
Pre-Tax Profit Margin -1,954.5
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $1,973,000
Revenue Per Share $0.0817
Revenue 3 Years $27.97
Revenue 5 Years $-4.93
Valuation Measures
PE Ratio -
Enterprise Value $33,505,325
Price To Sales 6.371695
Price To Free Cash -0.9
PE High Last 5 Years -
Price To Book 5.1
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 11.4
Financial Strength
Total Debt To Equity 10.1
Int Coverage -8.3
Current Ratio 1.4
Leverage Ratio 5.2
Quick Ratio 1.3
Long Term Debt To Capital 0.91
Assets
Receivables Turnover 6.5
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -48.47
Return On Equity -191.67
Return On Capital -46.73
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
AMEX
IBIO
iBio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.